- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01526759
Fiber Longer Term Study on Energy Intake (FLiTS)
The Effect of 2 Weeks of Supplementation of a High-gelling, High-viscous Dietary Fibre on Energy Intake
Dietary fibre seems to have a relevant role in body weight management. In an acute study the investigators found that high viscous-high gelling pectin increased feelings of satiety. The objective of this study is to study the effects of 2 weeks of supplementation of high gelling-high viscous fibre or a high gelling-high viscous non-fibre control on energy intake.
The investigators do this by measuring the difference in ad libitum energy intake after 15 days of pectin or 15 days of control supplements. The investigators will further measure differences in 24h feelings of satiety, fasting blood glucose and insulin, fermentation and composition of microbiota.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Wageningen, Pays-Bas, 7002HD
- Wageningen University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age: 18-30 year
- BMI: 18.5-25 kg/m2
- Healthy: as judged by the participant
- H2 producer
Exclusion Criteria:
- Weight loss or weight gain of more than 5 kg during the last 2 months
- Using an energy restricted diet during the last 2 months
- Lack of appetite for any reason
- Restrained eater
- Smoking
- Heavy alcohol use: >5 drinks/day
- Reported stomach or bowel diseases or disorders (e.g. irritable bowel syndrome)
- Reported diabetes
- Reported thyroid disease or any other endocrine disorder
- Using medication other than birth control, paracetamol, aspirin, hey fever and asthma
- Antibiotic use <2 months before the study
- Reported intolerance, allergy, or not liking of the research foods
- Vegetarian
- Current dietary fibre supplementation
- Fasting glucose levels >5.8 mmol/l
- Experienced any problems with drawing blood in the past
- Thesis students or employees of the division of Human Nutrition
- Volunteers who participated in the ProVe study
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: pectin
10 gram high gelling-high viscous fiber, added to a drink
|
15 days 1 daily consumption of a drink with 10g pectin added
|
Comparateur placebo: control
10g gelatin, added to a drink
|
15 days 1 daily consumption of a drink with 10g gelatin added
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Energy intake
Délai: change from placebo after 2 weeks
|
after 14 days of both intervention and placebo supplements ad libitum energy intake is measured for 3 days in a row.
The change in energy intake will be calculated.
|
change from placebo after 2 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
satiety
Délai: change from placebo after 1 day and 15 days
|
at day 1 and after 15 days of both supplement and placebo intake satiety is measured hourly over 1 day at waking hours.
The change in satiety will be calculated.
|
change from placebo after 1 day and 15 days
|
fasting glucose
Délai: change from placebo after day 0, 1 and 15
|
at day 0, 1 and day 15 of supplementation period fasting glucose is measured
|
change from placebo after day 0, 1 and 15
|
fasting insulin
Délai: change from placebo after day 0, 1 and 15
|
at day 0, 1 and day 15 of supplementation period fasting insulin is measured
|
change from placebo after day 0, 1 and 15
|
fasting leptin
Délai: change from placebo after day 0, 1 and 15
|
at day 0, 1 and day 15 of supplementation period fasting leptin is measured
|
change from placebo after day 0, 1 and 15
|
hydrogen in breath
Délai: change from placebo after day 2 and 15
|
at day 2 and at day 15 hydrogen is measured hourly over 1 day at waking hours
|
change from placebo after day 2 and 15
|
energy intake
Délai: change from placebo after day 0 and 1
|
before supplement intake and after 1 day of supplement 1-day ad libitum energy intake is measured.
The change in energy intake will be calculated.
|
change from placebo after day 0 and 1
|
body weight
Délai: change from placebo after day 0,1,2,14,15, 16 and 17
|
Each day the subject reports to the research center, body weight is measured.
The change in body weight compared to placebo will be calculated.
|
change from placebo after day 0,1,2,14,15, 16 and 17
|
adverse events
Délai: daily from day 0 to day 16
|
participants will be asked to register adverse events daily in a diary.
They are also asked to report ae's to the researchers.
number and type of AEs after fibre supplements will be compared to number and type of AEs after placebo supplements
|
daily from day 0 to day 16
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Edith Feskens, Prof, Wageningen University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- NL38515.081.11
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur En bonne santé
-
AstraZenecaParexelComplété
Essais cliniques sur LM pectin (10%)
-
Kangbuk Samsung HospitalComplétéMyomeCorée, République de
-
LaNova Medicines Development Co., Ltd.Shanghai Zhongshan Hospital; First Affiliated Hospital of Zhejiang University et autres collaborateursRésilié
-
LaNova Medicines LimitedRecrutement
-
LaNova Medicines Zhejiang Co., Ltd.Actif, ne recrute pas
-
LaNova Medicines LimitedRecrutement
-
LaNova Australia Pty LimitedRésiliéTumeur solide avancéeAustralie
-
Henan Cancer HospitalRecrutementNSCLC | Métastases cérébrales | Métastase leptoméningéeChine
-
LaNova Medicines LimitedRésilié
-
LaNova Medicines LimitedRésilié
-
Lawson Health Research InstituteUniversity of Western Ontario, CanadaComplétéCancer du col de l'utérus | Cancer de la vulveCanada